Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis
Open Access
- 1 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (8), 1352-1357
- https://doi.org/10.1093/rheumatology/kes417
Abstract
Advances in the treatment of RA in the past decade have been achieved mainly by using combinations of different conventional and biologic DMARDs. However, until now no final victory has been achieved over this organ damaging and potentially life-threatening systemic autoimmune disease. Few patients, notably those with established disease, stay in remission permanently, even using advanced treatment concepts. Thus novel approaches, especially for patients resistant to biologics, are urgently needed. Pro-inflammatory signalling pathways beyond the level of cytokines and receptors have been intensively elaborated and provide such potential targets. This review focuses on the development of new small molecule inhibitors of Janus kinases in clinical trials in RA.Keywords
This publication has 8 references indexed in Scilit:
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid ArthritisNew England Journal of Medicine, 2012
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid ArthritisNew England Journal of Medicine, 2012
- Kinase Inhibition — A New Approach to the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2012
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant RejectionJournal of Medicinal Chemistry, 2010
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJournal of Inflammation, 2010
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placeboArthritis & Rheumatism, 2009
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 InhibitorScience, 2003